In its COVID-19 treatment guidelines, the National Institutes of Health (NIH) lists several drugs commonly prescribed for patients with rheumatic conditions as potential therapies in those who are hospitalized for COVID-19 and require high-flow oxygen, noninvasive ventilation, intermittent ventilation (IMV) or extracorporeal membrane oxygenation (ECMO), as of Aug. 25, 2021, and current as this is…
A 44-year-old woman presented to the emergency department with bifrontal headaches that had started approximately one month earlier. She was diagnosed with migraines and discharged home. Three days later, the patient returned to the emergency department upon recurrence of her headaches, and this time she also reported abnormal leg movements. A computerized tomography (CT) scan…
At the 17th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases meeting, Clifton Bingham, MD, delves into research into rheumatoid arthritis at the cellular level.
The ISC has worked with CVS Caremark to revisit changes to its prior authorization forms that would have increased the administrative burden on practices, and patients with Blue Cross Blue Shield of South Carolina may not have to worry about switching to a self-administered biologic.
Although effective against rheumatic disease, biologic therapies come with hefty price tags. Patient assistance programs can be a useful resource to help under- and uninsured patients get the drugs they need.
According to research, Pim kinases contribute to the pathogenesis of rheumatoid arthritis (RA) and may have the therapeutic potential for inhibition in patients with RA.
Research has identified and described a pro-inflammatory cytokine network shared by four rheumatic conditions that may be particularly active in patients with severe disease.
Melissa Griffith, MD, discussed the diagnosis and treatment of interstitial lung disease (ILD) in patients with rheumatic diseases, including connective tissue disease and more.
Immune checkpoint inhibitors (ICIs), such as anti-programmed cell-death 1/programmed death-ligand 1 (anti-PD-1/PD-L1) or anti-CTL-associated protein (anti-CTLA-4), have dramatically changed the treatment of advanced cancers over the past decade. ICIs block T cell inhibition, thus increasing the anti-tumor immune response. ICIs are used not only for metastatic cancer, but also as adjuvant treatment for some stage…
Options to escalate treatment for refractory inflammatory myositis and new therapies in the pipeline are discussed.